Skip to content
Peptide research

NA-Selank Amidate

Also known as N-Acetyl Selank Amidate · Acetylated Selank
Category
Brain & Cognition
Administration routes
Nasal
Regulatory status
Not FDA-approved

A stabilized analog of Selank, marketed for calming anxiety without sedation or dependence. Human evidence is only moderate and mostly borrowed from the parent molecule; BDNF and antidepressant claims are animal or mechanism only. No trials exist on this exact form, so human safety data is essentially absent, with unresolved immune and serotonergic questions. Not an approved drug in the US or Europe, and supply is unregulated research-grade material.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

NA-Selank Amidate (N-Acetyl Selank Amidate) is a chemically modified version of Selank, the anxiolytic nootropic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. The modifications — N-acetylation of the N-terminal threonine and C-terminal amidation — are specifically designed to enhance metabolic stability, extend the peptide's biological half-life, and improve its ability to cross biological membranes, including the blood-brain barrier.

Selank itself is a synthetic analog of the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro tail that dramatically increases its duration of action. Selank modulates the expression of interleukin-6, influences the balance of T-helper cell cytokines, induces serotonin metabolism, and rapidly elevates brain-derived neurotrophic factor (BDNF) expression in the hippocampus. It also inhibits enkephalinase enzymes, potentially increasing endogenous enkephalin levels to produce anxiolytic effects without the sedation or dependence risk of benzodiazepines.

The NA-Amidate modification addresses a key limitation of the parent peptide — rapid enzymatic degradation by aminopeptidases (cleaving from the N-terminus) and carboxypeptidases (cleaving from the C-terminus). N-acetylation blocks aminopeptidase attack while C-terminal amidation blocks carboxypeptidase degradation, together producing a significantly more stable molecule. This is a common medicinal chemistry strategy used across many therapeutic peptides. NA-Selank Amidate is primarily used in research and peptide therapy contexts where extended stability and potentially greater CNS penetration are desired compared to unmodified Selank.

How it works in the body

An enhanced version of Selank (a synthetic analog of the immunomodulatory peptide tuftsin) with N-acetyl and C-terminal amide modifications that increase enzymatic stability and nasal bioavailability. Its proposed effects are extrapolated from parent Selank; anxiolysis and freedom from sedation or dependence have not been established for this analog.

Research overview

Research on NA-Selank Amidate specifically is limited, as most published studies involve the parent compound Selank. The modifications (N-acetyl, C-amide) are well-established peptide stabilization techniques that are expected to preserve the pharmacological profile while extending half-life. Selank research includes: (1) Anxiolytic effects — Selank has been compared with benzodiazepines in clinical studies in Russia and shown anxiolytic effects without sedation or dependence. It is approved as a nasal spray in Russia for generalized anxiety disorder. (2) Immunomodulation — Selank modulates IL-6 expression, affects T-helper cell cytokine balance, and mimics many effects of its parent peptide tuftsin (Uchakina et al.). (3) BDNF elevation — Selank rapidly increases BDNF expression in rat hippocampus. (4) Serotonin modulation — Selank induces serotonin metabolism and affects the expression of genes related to the serotonin system. (5) Enkephalinase inhibition — Both Selank and Semax inhibit enzymes that degrade enkephalins, potentially boosting endogenous opioid peptide levels. (6) Gene expression — Microarray studies show Selank affects expression of 36+ genes involved in GABAergic signaling, neurotransmission, and immune function. Approximately 50-80 PubMed publications exist on Selank, with most in Russian-language journals.

Who researches NA-Selank Amidate?

Commonly researched by

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People researching immune system support

    Studied for immune modulation, antiviral, or antimicrobial properties.

  • People researching inflammation management

    Studied for anti-inflammatory effects across various conditions.

  • People exploring anxiety and stress management

    Researched for anxiolytic or stress-reducing properties.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(3)

Rated by level of concern

  • Limited safety data (no formal clinical trials on the NA-Amidate form)

    Moderate

    Absence of indexed literature (PubMed, ClinicalTrials.gov); parent-compound tolerability from PMID 18454096, 25176261, 26356395

  • Potential immunomodulatory effects (IL-6, cytokine balance)

    Moderate

    PMID 18577961; PMID 21609736; PMID 24291245; PMID 32621722

  • Possible serotonergic interactions

    Theoretical

    PMID 19803361; PMID 19093364 (mechanistic basis only — no reported human interaction events)

Interaction summary(7)

Rated by direction with this peptide

  • Benzodiazepines (diazepam, phenazepam, medazepam)

    SynergisticLow

    Combined Selank + diazepam was the most effective condition for reducing anxiety in rats under unpredictable chronic mild stress, though Selank alone was most effective in the non-stressed arm (PMID 28280289). In humans, adding Selank to phenazepam accelerated onset on HDRS and reduced phenazepam's side effects (sedation, attention/memory impairment, asthenia) both during treatment and after tranquilizer withdrawal (PMID 26356395) — i.e. the documented human interaction is favorable rather than harmful. Severity kept Low because no adverse combined-use event has been reported and Selank is non-sedating; still, dose adjustment of the benzodiazepine is a reasonable precaution and no data exist for the NA-amidate form.

    PMID 28280289; PMID 26356395

  • Alcohol / chronic ethanol exposure and withdrawal

    ProtectiveLow

    In rats with chronic ethanol exposure, Selank protected against ethanol-induced memory impairment while regulating BDNF content in hippocampus and prefrontal cortex (PMID 31625062) — animal-only, with no human data supporting use in alcohol use disorder and no evidence about co-ingestion with alcohol in people.

    PMID 31625062

  • Opioids (morphine; opioid withdrawal states)

    ProtectiveLow

    A single intraperitoneal injection of Selank reduced the total morphine-withdrawal index by ~40% in naloxone-precipitated withdrawal in rats, slightly inferior to diazepam (PMID 36322304). Consistent with effects on enkephalin turnover — the human trial reported increased leu-enkephalin half-life in serum during Selank treatment (PMID 18454096). Both are indirect: no human opioid co-administration study exists, and the same enkephalin effect is an equally plausible theoretical basis for altered opioid response in either direction.

    PMID 36322304; PMID 18454096

  • SSRIs, SNRIs, MAOIs and other serotonergic agents

    CautionTheoretical

    Selank measurably alters brain serotonin metabolism and monoamine turnover in rodents (PMID 19803361, PMID 19093364), so additive serotonergic effects are conceivable on paper, but no reuptake-inhibition or MAO-inhibition activity has been shown, no serotonin-syndrome case has ever been reported, and no formal interaction study exists.

    PMID 19803361; PMID 19093364

  • Immunosuppressants, biologics and cytokine-directed therapy (e.g. IL-6 or TNF inhibitors)

    CautionTheoretical

    Selank altered IL-6 in patient blood cell cultures and shifted Th1/Th2 balance in treated patients' serum (PMID 18577961), and broadly modulated inflammation-related gene expression in mice (PMID 21609736, PMID 24291245), so it could in principle work against or unpredictably alongside therapy that deliberately targets those pathways — no co-administration has been studied in any species.

    PMID 18577961; PMID 21609736; PMID 24291245

  • Autoimmune and chronic inflammatory disease (as a clinical context rather than a drug)

    CautionTheoretical

    As a tuftsin analog with measured cytokine-shifting activity in patients (PMID 18577961), Selank has never been tested in anyone with active autoimmune or inflammatory disease, and the net direction of its immune effect in those populations is unknown.

    PMID 18577961; absence of trials enrolling immune-compromised or autoimmune patients

  • Intranasal corticosteroids, decongestants and nasal-mucosa-altering agents

    CautionTheoretical

    Route-based inference only. If the compound is used intranasally, anything that changes mucosal blood flow, mucus clearance, or epithelial integrity could alter absorption unpredictably. Note that the nasal-bioavailability advantage claimed for the amidated form is itself unpublished, and there is no pharmacokinetic study of Selank or its analogs under co-administered nasal agents.

    Mechanism/route-based inference; no published PK interaction data for Selank or the NA-amidate form

Known risks(3)

  • Limited safety data (no formal clinical trials on the NA-Amidate form)

    While the parent compound Selank has a favorable safety profile in Russian clinical use, the specific NA-Amidate modification has not been clinically tested. Safety is extrapolated from Selank data and general peptide modification principles.

  • Potential immunomodulatory effects (IL-6, cytokine balance)

    Mild (theoretical)

    Selank modulates immune function through IL-6 and T-helper cell cytokine balance. Patients with autoimmune conditions or those on immunosuppressive therapy should exercise caution.

  • Possible serotonergic interactions

    Mild to Moderate (theoretical)

    Selank affects serotonin metabolism. Combining with serotonergic medications could theoretically alter serotonin balance, though serotonin syndrome risk appears low based on available data.

Drug interactions(3)

  • SSRIs and SNRIs (sertraline, fluoxetine, venlafaxine)

    Selank affects serotonin metabolism. Combining with serotonergic antidepressants could theoretically alter serotonin balance. Monitor for increased serotonergic effects.

  • Benzodiazepines (diazepam, alprazolam, lorazepam)

    Selank has been compared with benzodiazepines for anxiolytic efficacy. Additive anxiolytic effects are possible when combined. May allow for benzodiazepine dose reduction but clinical guidance is lacking.

  • Immunosuppressive medications

    Selank has immunomodulatory effects (IL-6 modulation, tuftsin-like activity). Combining with immunosuppressants could produce unpredictable effects on immune function.

Research & benefits

Evidence base

Evidence Level
Very Limited Evidence
Total Studies
70
Human Studies
0 participants in identified clinical studies of NA-Selank Amidate.

Selank (the parent compound) is registered in Russia as an anxiolytic supplied as nonprescription nasal drops and has been studied in several Russian clinical trials for anxiety and cognitive disorders. English-language clinical data is scarce — most published studies are pilot studies or have only abstracts available in English. NA-Selank Amidate specifically has not been tested in clinical trials. The modifications are expected to enhance stability without altering the pharmacological profile significantly, but this has not been clinically validated.

Researched for(6)

Rated by confidence in the evidence

  • Anxiolytic effects comparable to benzodiazepines without sedation or dependence risk

    Medium

    Small non-blinded trials of parent Selank, not this analog, matched benzodiazepine anxiolysis; dependence untested.

    PMID 18454096; PMID 25176261; PMID 26356395

  • Rapid elevation of BDNF expression in hippocampus

    Low

    Rat studies show parent Selank regulates hippocampal BDNF; no human or NA-amidate data exist.

    PMID 18841804; PMID 31625062

  • Immunomodulatory effects — IL-6 modulation, T-helper cell cytokine balance

    Medium

    Human data limited to lab-cultured cells and one small uncontrolled trial; animal evidence is consistent.

    PMID 18577961; PMID 21609736; PMID 24291245; PMID 32621722

  • Enhanced metabolic stability vs parent Selank (N-acetyl + amide modifications)

    Speculative

    No published studies on this specific molecule, based only on general peptide-stability chemistry.

    No primary source located; mechanism-only inference from established peptide-modification chemistry

  • Modulation of serotonin metabolism and related gene expression

    Low

    Consistent rat and mouse data on serotonin metabolism; no human studies or NA-amidate testing.

    PMID 19803361; PMID 19093364; PMID 18197389; PMID 26924987 (GABAergic genes, adjacent claim); PMID 8704608 (tuftsin/TP-7, not Selank)

  • Antidepressant-like effects in animal models of depression and anhedonia

    Speculative

    One rat and mouse study, inconsistent across doses and models; no human antidepressant trials.

    PMID 18661785; PMID 16963804

Benefits(6)

  • Anxiolytic effects comparable to benzodiazepines without sedation or dependence risk

    Russian clinical studies (Selank); Seredenin et al., Bull Exp Biol Med 2002

  • Rapid elevation of BDNF expression in hippocampus

    Inozemtseva et al., Doklady Biological Sciences 2008 (parent Selank, rat hippocampus; PMID 18841804)

  • Immunomodulatory effects — IL-6 modulation, T-helper cell cytokine balance

    Uchakina et al. (Selank/tuftsin analog immunology studies)

  • Enhanced metabolic stability vs parent Selank (N-acetyl + amide modifications)

    General peptide medicinal chemistry literature; modification-specific data limited

  • Modulation of serotonin metabolism and related gene expression

    PMC4757669 (Selank gene expression study); Semenova et al. 2010

  • Antidepressant-like effects in animal models of depression and anhedonia

    Sarkisova et al., Bull Exp Biol Med 2008 (Selank, WAG/Rij rat model)

Key studies(2)

  1. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission

    Preclinical (gene expression)Rat brain tissue1 and 3 hours after administration

    Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P

    Frontiers in Pharmacology (PMC)

    2016

    Parent Selank altered 29 tested genes at 1 hour and 17 at 3 hours in rat frontal cortex, supporting a proposed GABAergic mechanism.

  2. Multiple contributors (Wikipedia)

    Wikipedia

    2024

    Selank is a synthetic tuftsin analog with demonstrated anxiolytic, nootropic, and immunomodulatory effects. It modulates IL-6, serotonin, BDNF, and enkephalinase activity. Approved in Russia as a nasal spray for anxiety disorders.

Regulation & availability

Why researchers look at it

The cited clinical trial concerns parent Selank. It does not establish clinical benefits, dependence risk or comparative stability for NA-Selank Amidate.

FDA status
NA-Selank Amidate is not FDA-approved and is not eligible for compounding in the US. Parent Selank is registered in Russia as an anxiolytic supplied as 0.15% nonprescription nasal drops. That registration does not cover NA-Selank Amidate.
WADA status
NA-Selank Amidate is not individually named on the 2026 WADA Prohibited List. If it lacks current governmental approval anywhere for human therapeutic use and is not covered elsewhere on the List, S0 prohibits it at all times. Parent Selank's registration does not establish approval of this analog.
Prescribability
No — Not approved by FDA or any major regulatory agency. Parent compound Selank approved in Russia.
Availability
It is not available as an approved pharmaceutical product in any country. The parent compound Selank is available as nonprescription nasal drops (0.15% solution) in Russia and can be obtained from Russian pharmacies.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(5)

  1. 1990s
    Selank developed at Institute of Molecular Genetics, Russian Academy of Sciences
  2. 2000s
    Selank approved as prescription anxiolytic nasal spray in Russia
  3. 2002
    Early publications on Selank's anxiolytic and nootropic effects
  4. 2008
    Parent Selank shown to regulate BDNF expression in rat hippocampus
  5. 2016
    GABAergic gene expression effects of Selank characterized

Sources & FAQs

Research sources(3)

Frequently asked questions(3)

What do the 'NA' and 'Amidate' modifications do?

The 'NA' (N-Acetyl) modification adds an acetyl group to the peptide's N-terminal amino acid, protecting it from aminopeptidase enzymes that would otherwise rapidly degrade it. The 'Amidate' modification replaces the C-terminal carboxyl group with an amide group, protecting against carboxypeptidase degradation. Together, these modifications significantly extend the peptide's half-life and may improve absorption and CNS penetration.

How does NA-Selank Amidate differ from regular Selank?

NA-Selank Amidate has the same core amino acid sequence as Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) but with two chemical modifications that increase resistance to enzymatic degradation. This means it is expected to last longer in the body and potentially produce more consistent effects at lower doses. However, head-to-head comparison studies between the two forms have not been published.

Is NA-Selank Amidate addictive like benzodiazepines?

Research on the parent compound Selank suggests it produces anxiolytic effects through a mechanism distinct from benzodiazepines — primarily through serotonergic modulation, BDNF elevation, and enkephalinase inhibition rather than direct GABA-A receptor potentiation. Selank has not shown dependence potential or withdrawal effects in preclinical or clinical studies.